371 related articles for article (PubMed ID: 8347292)
1. Genetically determined adverse drug reactions involving metabolism.
Lennard MS
Drug Saf; 1993 Jul; 9(1):60-77. PubMed ID: 8347292
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
3. Clinical consequences of polymorphic drug oxidation.
Alván G
Fundam Clin Pharmacol; 1991; 5(3):209-28. PubMed ID: 1937350
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
5. [Knowledge about metabolic capacity is important in drug therapy].
Alván G; Dahl ML
Lakartidningen; 1992 Feb; 89(6):382, 387-90. PubMed ID: 1738265
[TBL] [Abstract][Full Text] [Related]
6. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
7. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics.
Wolf CR; Smith G
Br Med Bull; 1999; 55(2):366-86. PubMed ID: 10723863
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetics of oxidation reactions of drugs].
Jacqz-Aigrain E
Arch Fr Pediatr; 1989 Jan; 46(1):59-65. PubMed ID: 2653266
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.
Shah RR
Expert Opin Drug Saf; 2005 Jan; 4(1):103-28. PubMed ID: 15709902
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Lennard MS
Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of the cytochromes P450.
Daly AK
Curr Top Med Chem; 2004; 4(16):1733-44. PubMed ID: 15579105
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
17. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
Kroemer HK; Eichelbaum M
Life Sci; 1995; 56(26):2285-98. PubMed ID: 7791516
[TBL] [Abstract][Full Text] [Related]
18. Genetically determined differences in drug metabolism as a risk factor in drug toxicity.
Eichelbaum M; Kroemer HK; Mikus G
Toxicol Lett; 1992 Dec; 64-65 Spec No():115-22. PubMed ID: 1471165
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]